A5100318023- Advanced Breast Cancer Therapies
- Gut microbiota and health
- HER2/EGFR in Cancer Research
- Immunotherapy and Immune Responses
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Neonatal Health and Biochemistry
- Berberine and alkaloids research
- Cholesterol and Lipid Metabolism
- RNA Interference and Gene Delivery
- Acute Ischemic Stroke Management
- PI3K/AKT/mTOR signaling in cancer
- ATP Synthase and ATPases Research
- Gastric Cancer Management and Outcomes
- Liver physiology and pathology
- Cancer Mechanisms and Therapy
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Animal Behavior and Welfare Studies
- Chemokine receptors and signaling
- vaccines and immunoinformatics approaches
- Salivary Gland Disorders and Functions
- Clostridium difficile and Clostridium perfringens research
First Hospital of Jilin University
2017-2025
Jilin University
2017-2025
First Affiliated Hospital of Jinan University
2024
General Hospital of Shenyang Military Region
2024
Shanghai Pulmonary Hospital
2024
Tongji University
2024
Kyoto University
2023-2024
Yunnan University
2024
Kyoto University Hospital
2023-2024
Sun Yat-sen University
2023
The performance of weaned piglets suffers from severe limitations resulting diarrhoea. Therefore, this trial was performed to investigate the effects Bacillus coagulans as an alternative antibiotics on piglet growth and intestinal health. Ninety (initial BW = 7.70 ± 0.17 kg, weaning age 26 days) healthy with similar BWs were selected randomised into three treatment groups. Pigs in negative control (NC) group fed a basal diet, pigs positive (PC) diet plus antibiotics, test (BC) at 600 g/t;...
Abstract Several chemotherapeutic drugs induce senescence in cancer cells; however, the mechanisms underlying intracellular pH dysregulation senescent cells remain unclear. Adenosine triphosphatase H + transporting accessory protein 2 (ATP6AP2) plays a critical role maintaining homeostasis cellular compartments. Herein, we report regulatory of ATP6AP2 breast treated with doxorubicin (Doxo) and abemaciclib (Abe). A decline triggers aberrant levels that impair lysosomal function cause immune...
392 Background: NIVO + chemo demonstrated clinically meaningful survival benefit and an acceptable safety profile vs in previously untreated Chinese pts with advanced GC/GEJC/EAC from CheckMate 649, consistent the overall study population. 1L is currently approved for non-HER2+ China other countries. We report 5-y results of 649. Methods: Adults untreated, unresectable or metastatic, were enrolled regardless programmed death ligand 1 (PD-L1) expression. Randomized received chemo, ipilimumab,...
Abstract Lipids are a major component of extracellular vesicles; however, their significance in tumorigenesis and progression has not been well elucidated. As we previously found that lipid profiles drastically changed breast tumors upon progression, hypothesized plasma‐derived vesicles could be utilized as cancer biomarkers. Here, adopted modified sucrose cushion ultracentrifugation to isolate from ( n = 105), benign 11), healthy individuals 43) two independent cohorts 126 33) conducted...
Abstract Background Although DNA vaccine holds a great potential for cancer immunotherapy, effective long-lasting antitumoral immunity sufficient to induce durable responses in patients remains be achieved. Considering the pivotal role of dendritic cells (DC) antigen processing and presentation, we prepared DC-targeting vaccines by fusing tumor-associated HER2/neu ectodomain single chain antibody fragment (scFv) from NLDC-145 specific DC-restricted surface molecule DEC-205 (scFv ), explored...
Multiple tumors are synergistically promoted by c-Met and TRK, blocking their cross-signalling pathway may give better effects. In this study, we developed a tyrosine kinase inhibitor 1D228, which exhibited excellent anti-tumor activity targeting TRK. Models in vitro, 1D228 showed significant inhibition on cancer cell proliferation migration than the positive drug Tepotinib. vivo, robust effect gastric liver tumor growth with 94.8% 93.4% of TGI, respectively, comparing 67.61% 63.9%...
Abstract Background: Abemaciclib, a CDK4/6 inhibitor, stands as cornerstone for managing hormone receptor-positive, HER2-negative advanced or metastatic recurrent breast cancer. It is known to modulate the tumor immune microenvironment, enhancing anti-tumor responses. Yet, its systemic immunological impact remains be elucidated. This investigation aims delineate influence of abemaciclib on both gut microbiota and landscape in patients with Methods: A multicenter, prospective clinical trial...
Abstract Background: Abemaciclib, a leading treatment used for HR-positive, HER2-negative metastatic and primary breast cancer patients, often causes diarrhea. Understanding the reasons machinery behind this adverse event leads to reduce toxicity improve quality of life. This study explores hypothesis that specific gut microbiota profiles are engaged in gastrointestinal toxicities caused by abemaciclib may be influenced patients' dietary habits. We assessed it using Brief Diet History...
Rationale/Aim Intracranial atherosclerotic stenosis (ICAS) is a common cause of stroke in Asia and significantly associated with recurrence. The Balloon angiopLasty for intracranial Atherosclerotic minor Stroke/TIA (BLAST) study aims to evaluate the safety effectiveness early submaximal balloon angioplasty (SBA) combined standard medical therapy vs. alone patients or transient ischemic attack (TIA) due ICAS. Methods BLAST multicenter prospective cohort which will enroll TIA symptomatic ICAS...
e14580 Background: LBL-019 is a humanized monoclonal IgG1 antibody against TNF receptor 2 (TNFR2). It specifically binds to TNFR2 with high affinity, co-stimulates in Fc crosslinking-dependent manner, results activation of NF-κB signaling and T cell expansion, promoting antitumor immunity. Here we report the preliminary safety efficacy patients advanced malignant tumors. Methods: This phase Ⅰ, open-label, multicenter, dose-escalation study evaluate safety, tolerability, PK solid tumors that...
Abstract Background: Chidamide is an oral subtype-selective histone deacetylase inhibitor. The ACE study demonstrated that chidamide plus exemestane improved progression-free survival compared with placebo in patients (pts) advanced, HR-positive, HER2-negative breast cancer progressed after previous endocrine therapy. This phase 2 aims to evaluate the efficacy and safety of fulvestrant treatment HR-positive advanced had Methods: Eligible pts were women aged 18-75 years histologically...
Results: Interestingly, in subgroup analysis of rs1045642 ABCB1 gene, a significant difference was found with greater progression free survival (PFS) the AA homozygous group compared to heterozygous alleles ( p = 0.002, Bonferroni correction).Rs2032582 gene also presented heterogeneous distribution 0.03), showing PFS that clearly favors state.The 7 cases present mean 34.71, 21 state 15.9, and GG presents ILP 23.38 months.RS2242480 encoding CYP3A4 had been CC (29 cases) heterozygosis CT (6...
Abstract Background: Pyrotinib, a newly-developed irreversible pan-ErbB inhibitor, has shown promising antitumor activity and acceptable tolerability in phase 1-3 studies. However, findings from randomized clinical trials may have limited generalizability to patients treated routine practice. Herein, we conducted this multicenter real-world study examine the treatment patterns, effectiveness safety of pyrotinib-based therapy human epidermal growth factor receptor 2 (HER2)-positive breast...
Abstract Background: Stable humanized immune mice transplanted with peripheral blood mononuclear cells (PBMCs) derived from breast cancer patients are important models for assessing the tumor responses and microenvironment in cancer, helping to advance both pre-clinical clinical research. The PBMCs of exhibit various differences those healthy individuals depending on stage progression, subtype, type treatment. Recent studies indicate an association self-renewal signatures T successful...